Anti-inflammatory; highly selective inhibitor of COX-1 (ratio of IC50 values for COX-2/COX-1 ~ 600).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 331.35. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.02 mL||15.09 mL||30.18 mL|
|5 mM||0.6 mL||3.02 mL||6.04 mL|
|10 mM||0.3 mL||1.51 mL||3.02 mL|
|50 mM||0.06 mL||0.3 mL||0.6 mL|
References are publications that support the products' biological activity.
Mitchell et al (1995) Cyclooxygenase-2. Regulation and relevance in inflammation. Biochem.Pharmacol. 50 1535 PMID: 7503754
If you know of a relevant reference for Piroxicam, please let us know.
View Related Products by Product Action
Keywords: Piroxicam, supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, COX, Oxygenases, Oxidases, Cyclooxygenase, Cyclooxygenase, Tocris Bioscience
Citations for Piroxicam
Citations are publications that use Tocris products.
Currently there are no citations for Piroxicam. Do you know of a great paper that uses Piroxicam from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.